Cambridge Heart
This article was originally published in The Gray Sheet
Executive Summary
Equity capital of $5.1 mil is raised via private placement, "primarily with a group of institutional investors," the firm reports. The financing included about 1.45 mil. unregistered common shares and 291,428 warrants. The Bedford, Massachusetts company will use a portion of the proceeds to further promote clinical adoption of its CH 2000 T-wave alternans test, cleared by FDA via 510(k) in April as the first non-invasive test to identify patients at risk of arrhythmia (1"The Gray Sheet" April 19, p. 11). Funds are also earmarked for additional clinical studies, pursuit of third-party reimbursement and "other operational needs"
You may also be interested in...
Cambridge Heart's CH 2000 Cleared To Include SCA Prognostic Indication
Cambridge Heart, Inc., expects its proprietary high-resolution electrode leads to generate additional revenue following FDA clearance of the CH 2000 T-wave alternans stress test 510(k) April 13 for the prognosis of sudden cardiac arrest.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.